➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Boehringer Ingelheim
Moodys
Express Scripts
McKinsey

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

BUMETANIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Bumetanide patents expire, and what generic alternatives are available?

Bumetanide is a drug marketed by Athenex Inc, Hospira, Teva Parenteral, West-ward Pharms Int, Amneal Pharms Co, Heritage Pharma, Rising, Sandoz, Upsher Smith Labs, and Zydus Pharms. and is included in eleven NDAs.

The generic ingredient in BUMETANIDE is bumetanide. There are six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the bumetanide profile page.

US ANDA Litigation and Generic Entry Outlook for Bumetanide

A generic version of BUMETANIDE was approved as bumetanide by HOSPIRA on October 31st, 1994.

  Start Trial

Drug patent expirations by year for BUMETANIDE
Drug Prices for BUMETANIDE

See drug prices for BUMETANIDE

Drug Sales Revenue Trends for BUMETANIDE

See drug sales revenues for BUMETANIDE

Recent Clinical Trials for BUMETANIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lawson Health Research InstituteN/A
Hospital General de México Dr. Eduardo LiceagaPhase 4
B&A TherapeuticsPhase 2

See all BUMETANIDE clinical trials

Pharmacology for BUMETANIDE
Medical Subject Heading (MeSH) Categories for BUMETANIDE

US Patents and Regulatory Information for BUMETANIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Athenex Inc BUMETANIDE bumetanide INJECTABLE;INJECTION 074441-001 Jan 27, 1995 DISCN No No   Start Trial   Start Trial   Start Trial
Upsher Smith Labs BUMETANIDE bumetanide TABLET;ORAL 209916-001 Jan 23, 2018 AB RX No No   Start Trial   Start Trial   Start Trial
Amneal Pharms Co BUMETANIDE bumetanide TABLET;ORAL 209724-002 Oct 18, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Teva Parenteral BUMETANIDE bumetanide INJECTABLE;INJECTION 074613-001 Nov 18, 1997 DISCN No No   Start Trial   Start Trial   Start Trial
Rising BUMETANIDE bumetanide TABLET;ORAL 212019-001 Dec 12, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Upsher Smith Labs BUMETANIDE bumetanide TABLET;ORAL 209916-003 Jan 23, 2018 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Express Scripts
Colorcon
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.